COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cogent Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$30.01+0.49 (+1.66%)
Close on Oct 19, 2026
- Market cap
- $5.13B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -56.2% | -73.7% | |
| Return on assets | – | -49.8% | -52.0% | |
| Current ratio | – | 18.70 | 14.23 | |
| Capex to revenue | – | – | – | |
| Diluted shares | – | 11M | 129M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cogent Biosciences generated $803.26M from operations and spent $13.51M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$803.26M
Used
$13.51M
Capital expenditure$13.51M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-950.4%
×Asset turnover0.05×
×Equity multiplier1.13×
=Return on equity, FY2020-56.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2020 | -950.4% | 0.05× | 1.13× | -56.2% |
| FY2019 | -141.5% | 0.33× | 1.47× | -69.2% |
| FY2018 | -354.8% | 0.14× | 11.86× | -606.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$328.94M
- Cash generatingOperating cash flow above zero-$264.44M
- Return on assets improvedROA up on the prior year-81.6% → -100.3%
- Earnings backed by cashOperating cash flow above net income-$264.44M vs -$328.94M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose5.32 → 14.23
- No dilutionShare count did not rise104M → 129M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –